MedTrace Logo

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

NCT05887726 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-07-27

No results posted yet for this study

Summary

This study is a prospective, open-label, single-arm phase II clinical study to evaluate the safety and efficacy of zanubrutinib plus R-CHOP (ZR-CHOP) as the first-line therapy for newly diagnosed diffuse large B-cell lymphoma patients with high-risk factors.

Conditions

Interventions

DRUG

Zanubrutinib

Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)

DRUG

Rituximab

Rituximab 375 mg/m2 i.v d0(21-day cycles)

DRUG

Cyclophosphamide

Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)

DRUG

Epirubicin

Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)

DRUG

Vincristine

Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)

DRUG

Prednisone

Prednisone 100 mg p.o d1-d5 (21-day cycles)

Sponsors & Collaborators

  • Liaoning Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Xiaojing Xing, Ph.D · Liaoning Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-08-01
Completion
2025-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05887726 on ClinicalTrials.gov